nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—PTGS2—thyroid cancer	0.582	1	CbGaD
Pomalidomide—CYP1A2—Sorafenib—thyroid cancer	0.0307	0.243	CbGbCtD
Pomalidomide—ABCB1—Sorafenib—thyroid cancer	0.0268	0.212	CbGbCtD
Pomalidomide—CYP3A4—Vandetanib—thyroid cancer	0.0267	0.211	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—thyroid cancer	0.0163	0.129	CbGbCtD
Pomalidomide—CYP3A4—Sorafenib—thyroid cancer	0.0161	0.127	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—thyroid cancer	0.00976	0.0772	CbGbCtD
Pomalidomide—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00332	0.0834	CbGpPWpGaD
Pomalidomide—Lenalidomide—PTGS2—thyroid cancer	0.00296	0.625	CrCbGaD
Pomalidomide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00249	0.0627	CbGpPWpGaD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—THRB—thyroid cancer	0.00209	0.0525	CbGpPWpGaD
Pomalidomide—Thalidomide—PTGS2—thyroid cancer	0.00177	0.375	CrCbGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00149	0.0374	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00142	0.0358	CbGpPWpGaD
Pomalidomide—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00135	0.0341	CbGpPWpGaD
Pomalidomide—Angiopathy—Vandetanib—thyroid cancer	0.00103	0.00419	CcSEcCtD
Pomalidomide—Dehydration—Sorafenib—thyroid cancer	0.00103	0.00418	CcSEcCtD
Pomalidomide—Mediastinal disorder—Vandetanib—thyroid cancer	0.00102	0.00416	CcSEcCtD
Pomalidomide—Lymphopenia—Doxorubicin—thyroid cancer	0.00101	0.00414	CcSEcCtD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—RXRA—thyroid cancer	0.00101	0.0255	CbGpPWpGaD
Pomalidomide—Dry skin—Sorafenib—thyroid cancer	0.00101	0.00412	CcSEcCtD
Pomalidomide—Hypokalaemia—Sorafenib—thyroid cancer	0.001	0.0041	CcSEcCtD
Pomalidomide—Breast disorder—Sorafenib—thyroid cancer	0.000996	0.00407	CcSEcCtD
Pomalidomide—Mental disorder—Vandetanib—thyroid cancer	0.00099	0.00404	CcSEcCtD
Pomalidomide—Nasopharyngitis—Sorafenib—thyroid cancer	0.000986	0.00402	CcSEcCtD
Pomalidomide—Malnutrition—Vandetanib—thyroid cancer	0.000984	0.00402	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000972	0.00397	CcSEcCtD
Pomalidomide—Muscle spasms—Vandetanib—thyroid cancer	0.000946	0.00386	CcSEcCtD
Pomalidomide—Febrile neutropenia—Epirubicin—thyroid cancer	0.000933	0.00381	CcSEcCtD
Pomalidomide—Pelvic pain—Epirubicin—thyroid cancer	0.000923	0.00377	CcSEcCtD
Pomalidomide—Tremor—Vandetanib—thyroid cancer	0.000922	0.00376	CcSEcCtD
Pomalidomide—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0009	0.0226	CbGpPWpGaD
Pomalidomide—Neutropenia—Sorafenib—thyroid cancer	0.000891	0.00364	CcSEcCtD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—RXRA—thyroid cancer	0.000887	0.0223	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00088	0.0221	CbGpPWpGaD
Pomalidomide—Embolism—Epirubicin—thyroid cancer	0.000874	0.00357	CcSEcCtD
Pomalidomide—Febrile neutropenia—Doxorubicin—thyroid cancer	0.000863	0.00352	CcSEcCtD
Pomalidomide—Weight decreased—Sorafenib—thyroid cancer	0.000862	0.00352	CcSEcCtD
Pomalidomide—Cough—Vandetanib—thyroid cancer	0.000859	0.00351	CcSEcCtD
Pomalidomide—Pneumonia—Sorafenib—thyroid cancer	0.000854	0.00349	CcSEcCtD
Pomalidomide—Pelvic pain—Doxorubicin—thyroid cancer	0.000854	0.00348	CcSEcCtD
Pomalidomide—Infestation NOS—Sorafenib—thyroid cancer	0.000849	0.00347	CcSEcCtD
Pomalidomide—Infestation—Sorafenib—thyroid cancer	0.000849	0.00347	CcSEcCtD
Pomalidomide—Arthralgia—Vandetanib—thyroid cancer	0.000838	0.00342	CcSEcCtD
Pomalidomide—Renal failure—Sorafenib—thyroid cancer	0.000835	0.00341	CcSEcCtD
Pomalidomide—Anxiety—Vandetanib—thyroid cancer	0.000835	0.00341	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000833	0.0034	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000832	0.0034	CcSEcCtD
Pomalidomide—Embolism—Doxorubicin—thyroid cancer	0.000809	0.0033	CcSEcCtD
Pomalidomide—Hypercalcaemia—Epirubicin—thyroid cancer	0.000808	0.0033	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000803	0.00328	CcSEcCtD
Pomalidomide—Epistaxis—Sorafenib—thyroid cancer	0.000801	0.00327	CcSEcCtD
Pomalidomide—Infection—Vandetanib—thyroid cancer	0.000798	0.00326	CcSEcCtD
Pomalidomide—Nervous system disorder—Vandetanib—thyroid cancer	0.000788	0.00322	CcSEcCtD
Pomalidomide—Thrombocytopenia—Vandetanib—thyroid cancer	0.000786	0.00321	CcSEcCtD
Pomalidomide—Skin disorder—Vandetanib—thyroid cancer	0.00078	0.00318	CcSEcCtD
Pomalidomide—Urinary tract disorder—Sorafenib—thyroid cancer	0.000753	0.00307	CcSEcCtD
Pomalidomide—Connective tissue disorder—Sorafenib—thyroid cancer	0.000749	0.00306	CcSEcCtD
Pomalidomide—Urethral disorder—Sorafenib—thyroid cancer	0.000748	0.00305	CcSEcCtD
Pomalidomide—Hypercalcaemia—Doxorubicin—thyroid cancer	0.000747	0.00305	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000732	0.00299	CcSEcCtD
Pomalidomide—Insomnia—Vandetanib—thyroid cancer	0.000726	0.00297	CcSEcCtD
Pomalidomide—Dyspnoea—Vandetanib—thyroid cancer	0.000716	0.00292	CcSEcCtD
Pomalidomide—Cardiac disorder—Sorafenib—thyroid cancer	0.000708	0.00289	CcSEcCtD
Pomalidomide—Decreased appetite—Vandetanib—thyroid cancer	0.000698	0.00285	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000693	0.00283	CcSEcCtD
Pomalidomide—Fatigue—Vandetanib—thyroid cancer	0.000692	0.00283	CcSEcCtD
Pomalidomide—Angiopathy—Sorafenib—thyroid cancer	0.000692	0.00282	CcSEcCtD
Pomalidomide—Mediastinal disorder—Sorafenib—thyroid cancer	0.000687	0.00281	CcSEcCtD
Pomalidomide—Pain—Vandetanib—thyroid cancer	0.000687	0.0028	CcSEcCtD
Pomalidomide—Constipation—Vandetanib—thyroid cancer	0.000687	0.0028	CcSEcCtD
Pomalidomide—Mental disorder—Sorafenib—thyroid cancer	0.000668	0.00273	CcSEcCtD
Pomalidomide—Malnutrition—Sorafenib—thyroid cancer	0.000664	0.00271	CcSEcCtD
Pomalidomide—TNF—Transcription factor regulation in adipogenesis—PPARG—thyroid cancer	0.00064	0.0161	CbGpPWpGaD
Pomalidomide—Muscle spasms—Sorafenib—thyroid cancer	0.000638	0.00261	CcSEcCtD
Pomalidomide—Body temperature increased—Vandetanib—thyroid cancer	0.000635	0.00259	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000617	0.00252	CcSEcCtD
Pomalidomide—Anaemia—Sorafenib—thyroid cancer	0.000614	0.0025	CcSEcCtD
Pomalidomide—Hypocalcaemia—Epirubicin—thyroid cancer	0.000613	0.0025	CcSEcCtD
Pomalidomide—Leukopenia—Sorafenib—thyroid cancer	0.000594	0.00243	CcSEcCtD
Pomalidomide—Bone pain—Epirubicin—thyroid cancer	0.000586	0.00239	CcSEcCtD
Pomalidomide—Cough—Sorafenib—thyroid cancer	0.000579	0.00236	CcSEcCtD
Pomalidomide—Asthenia—Vandetanib—thyroid cancer	0.000576	0.00235	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000571	0.00233	CcSEcCtD
Pomalidomide—Pruritus—Vandetanib—thyroid cancer	0.000568	0.00232	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000568	0.00232	CcSEcCtD
Pomalidomide—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000567	0.00232	CcSEcCtD
Pomalidomide—TNF—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000566	0.0142	CbGpPWpGaD
Pomalidomide—Arthralgia—Sorafenib—thyroid cancer	0.000565	0.00231	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000561	0.00229	CcSEcCtD
Pomalidomide—Pulmonary embolism—Epirubicin—thyroid cancer	0.000561	0.00229	CcSEcCtD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—PPARG—thyroid cancer	0.00056	0.0141	CbGpPWpGaD
Pomalidomide—Hyperkalaemia—Epirubicin—thyroid cancer	0.000551	0.00225	CcSEcCtD
Pomalidomide—Diarrhoea—Vandetanib—thyroid cancer	0.00055	0.00224	CcSEcCtD
Pomalidomide—Bone pain—Doxorubicin—thyroid cancer	0.000542	0.00221	CcSEcCtD
Pomalidomide—Infection—Sorafenib—thyroid cancer	0.000538	0.0022	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—RET—thyroid cancer	0.000536	0.0135	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Sorafenib—thyroid cancer	0.000531	0.00217	CcSEcCtD
Pomalidomide—Dizziness—Vandetanib—thyroid cancer	0.000531	0.00217	CcSEcCtD
Pomalidomide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00053	0.00217	CcSEcCtD
Pomalidomide—Neuropathy—Epirubicin—thyroid cancer	0.000527	0.00215	CcSEcCtD
Pomalidomide—Skin disorder—Sorafenib—thyroid cancer	0.000526	0.00215	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000526	0.00215	CcSEcCtD
Pomalidomide—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000519	0.00212	CcSEcCtD
Pomalidomide—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.000515	0.0129	CbGpPWpGaD
Pomalidomide—Vomiting—Vandetanib—thyroid cancer	0.000511	0.00208	CcSEcCtD
Pomalidomide—Hyperkalaemia—Doxorubicin—thyroid cancer	0.00051	0.00208	CcSEcCtD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000509	0.0128	CbGpPWpGaD
Pomalidomide—Rash—Vandetanib—thyroid cancer	0.000506	0.00207	CcSEcCtD
Pomalidomide—Dermatitis—Vandetanib—thyroid cancer	0.000506	0.00207	CcSEcCtD
Pomalidomide—Headache—Vandetanib—thyroid cancer	0.000503	0.00205	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000498	0.0125	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000498	0.0125	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000494	0.00202	CcSEcCtD
Pomalidomide—Neuropathy—Doxorubicin—thyroid cancer	0.000488	0.00199	CcSEcCtD
Pomalidomide—Sepsis—Epirubicin—thyroid cancer	0.000487	0.00199	CcSEcCtD
Pomalidomide—CRBN—saliva-secreting gland—thyroid cancer	0.000484	0.194	CbGeAlD
Pomalidomide—Dyspnoea—Sorafenib—thyroid cancer	0.000483	0.00197	CcSEcCtD
Pomalidomide—Nausea—Vandetanib—thyroid cancer	0.000477	0.00195	CcSEcCtD
Pomalidomide—Decreased appetite—Sorafenib—thyroid cancer	0.000471	0.00192	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000468	0.00191	CcSEcCtD
Pomalidomide—Fatigue—Sorafenib—thyroid cancer	0.000467	0.00191	CcSEcCtD
Pomalidomide—Constipation—Sorafenib—thyroid cancer	0.000463	0.00189	CcSEcCtD
Pomalidomide—Pain—Sorafenib—thyroid cancer	0.000463	0.00189	CcSEcCtD
Pomalidomide—Sepsis—Doxorubicin—thyroid cancer	0.000451	0.00184	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000449	0.00183	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNA2—thyroid cancer	0.000436	0.011	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—NRG1—thyroid cancer	0.000434	0.0109	CbGpPWpGaD
Pomalidomide—Body temperature increased—Sorafenib—thyroid cancer	0.000428	0.00175	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—NRG1—thyroid cancer	0.000421	0.0106	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—LGALS3—thyroid cancer	0.000417	0.0105	CbGpPWpGaD
Pomalidomide—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000416	0.0017	CcSEcCtD
Pomalidomide—Hyponatraemia—Epirubicin—thyroid cancer	0.000409	0.00167	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—thyroid cancer	0.000407	0.00166	CcSEcCtD
Pomalidomide—Hypersensitivity—Sorafenib—thyroid cancer	0.000399	0.00163	CcSEcCtD
Pomalidomide—Asthenia—Sorafenib—thyroid cancer	0.000389	0.00159	CcSEcCtD
Pomalidomide—TNF—lymph node—thyroid cancer	0.000384	0.154	CbGeAlD
Pomalidomide—Pruritus—Sorafenib—thyroid cancer	0.000383	0.00156	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—thyroid cancer	0.000382	0.00156	CcSEcCtD
Pomalidomide—Dehydration—Epirubicin—thyroid cancer	0.000379	0.00155	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—thyroid cancer	0.000378	0.00155	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—thyroid cancer	0.000377	0.00154	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—thyroid cancer	0.000373	0.00152	CcSEcCtD
Pomalidomide—CRBN—trachea—thyroid cancer	0.000373	0.15	CbGeAlD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—RXRA—thyroid cancer	0.000372	0.00937	CbGpPWpGaD
Pomalidomide—Hypokalaemia—Epirubicin—thyroid cancer	0.000371	0.00151	CcSEcCtD
Pomalidomide—Diarrhoea—Sorafenib—thyroid cancer	0.000371	0.00151	CcSEcCtD
Pomalidomide—Breast disorder—Epirubicin—thyroid cancer	0.000368	0.0015	CcSEcCtD
Pomalidomide—Nasopharyngitis—Epirubicin—thyroid cancer	0.000364	0.00149	CcSEcCtD
Pomalidomide—Muscular weakness—Epirubicin—thyroid cancer	0.000359	0.00147	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000359	0.00147	CcSEcCtD
Pomalidomide—Dizziness—Sorafenib—thyroid cancer	0.000358	0.00146	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000353	0.00144	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—thyroid cancer	0.000351	0.00143	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—thyroid cancer	0.000346	0.00141	CcSEcCtD
Pomalidomide—Vomiting—Sorafenib—thyroid cancer	0.000344	0.00141	CcSEcCtD
Pomalidomide—Hypokalaemia—Doxorubicin—thyroid cancer	0.000343	0.0014	CcSEcCtD
Pomalidomide—Rash—Sorafenib—thyroid cancer	0.000342	0.00139	CcSEcCtD
Pomalidomide—Dermatitis—Sorafenib—thyroid cancer	0.000341	0.00139	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—thyroid cancer	0.000341	0.00139	CcSEcCtD
Pomalidomide—Headache—Sorafenib—thyroid cancer	0.000339	0.00139	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—thyroid cancer	0.000339	0.00138	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000337	0.00138	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—thyroid cancer	0.000334	0.00137	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000332	0.00136	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—thyroid cancer	0.000332	0.00136	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000332	0.00835	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000331	0.00833	CbGpPWpGaD
Pomalidomide—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000329	0.00829	CbGpPWpGaD
Pomalidomide—Neutropenia—Epirubicin—thyroid cancer	0.000329	0.00134	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000327	0.00134	CcSEcCtD
Pomalidomide—Nausea—Sorafenib—thyroid cancer	0.000322	0.00131	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—thyroid cancer	0.00032	0.00131	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—thyroid cancer	0.000319	0.0013	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000318	0.0013	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—thyroid cancer	0.000316	0.00129	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—thyroid cancer	0.000314	0.00128	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—thyroid cancer	0.000314	0.00128	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—thyroid cancer	0.000313	0.00128	CcSEcCtD
Pomalidomide—Pancytopenia—Doxorubicin—thyroid cancer	0.000309	0.00126	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—thyroid cancer	0.000309	0.00126	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IFNA2—thyroid cancer	0.000308	0.00775	CbGpPWpGaD
Pomalidomide—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.000308	0.00775	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000308	0.00126	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—thyroid cancer	0.000305	0.00125	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—thyroid cancer	0.000305	0.00124	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000303	0.00124	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NRG1—thyroid cancer	0.0003	0.00755	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000297	0.00121	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—thyroid cancer	0.000296	0.00121	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—thyroid cancer	0.000296	0.00121	CcSEcCtD
Pomalidomide—CRBN—thyroid gland—thyroid cancer	0.000295	0.119	CbGeAlD
Pomalidomide—Weight decreased—Doxorubicin—thyroid cancer	0.000295	0.0012	CcSEcCtD
Pomalidomide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000294	0.0012	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000294	0.00738	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.000292	0.00735	CbGpPWpGaD
Pomalidomide—Pneumonia—Doxorubicin—thyroid cancer	0.000292	0.00119	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—thyroid cancer	0.00029	0.00119	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—thyroid cancer	0.00029	0.00119	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—thyroid cancer	0.000286	0.00117	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CDK1—thyroid cancer	0.000285	0.00717	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000285	0.00116	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—thyroid cancer	0.000282	0.00115	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000279	0.00702	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000278	0.00114	CcSEcCtD
Pomalidomide—Oedema peripheral—Epirubicin—thyroid cancer	0.000278	0.00113	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—thyroid cancer	0.000277	0.00113	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—thyroid cancer	0.000276	0.00113	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000275	0.00112	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—thyroid cancer	0.000274	0.00112	CcSEcCtD
Pomalidomide—CRBN—head—thyroid cancer	0.000262	0.105	CbGeAlD
Pomalidomide—TNF—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000262	0.00658	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Epirubicin—thyroid cancer	0.000262	0.00107	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—thyroid cancer	0.000261	0.00657	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—BRAF—thyroid cancer	0.000259	0.00651	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000258	0.00649	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000258	0.00105	CcSEcCtD
Pomalidomide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000257	0.00105	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000256	0.00105	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—thyroid cancer	0.000256	0.00104	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—thyroid cancer	0.000256	0.00104	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000254	0.00104	CcSEcCtD
Pomalidomide—TNF—Signaling events mediated by HDAC Class I—PPARG—thyroid cancer	0.000254	0.00638	CbGpPWpGaD
Pomalidomide—Chills—Epirubicin—thyroid cancer	0.000253	0.00103	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—thyroid cancer	0.000247	0.00101	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—thyroid cancer	0.000245	0.001	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—RXRA—thyroid cancer	0.000245	0.00616	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000242	0.000988	CcSEcCtD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IFNA2—thyroid cancer	0.00024	0.00605	CbGpPWpGaD
Pomalidomide—Back pain—Epirubicin—thyroid cancer	0.000237	0.000969	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—thyroid cancer	0.000237	0.000966	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—thyroid cancer	0.000236	0.000963	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—PPARG—thyroid cancer	0.000235	0.00591	CbGpPWpGaD
Pomalidomide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000235	0.000959	CcSEcCtD
Pomalidomide—Chills—Doxorubicin—thyroid cancer	0.000234	0.000955	CcSEcCtD
Pomalidomide—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000232	0.00584	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.00023	0.00579	CbGpPWpGaD
Pomalidomide—Mental disorder—Doxorubicin—thyroid cancer	0.000228	0.000933	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—thyroid cancer	0.000227	0.000927	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—thyroid cancer	0.000227	0.000926	CcSEcCtD
Pomalidomide—Vertigo—Epirubicin—thyroid cancer	0.00022	0.0009	CcSEcCtD
Pomalidomide—Leukopenia—Epirubicin—thyroid cancer	0.00022	0.000897	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—thyroid cancer	0.00022	0.000896	CcSEcCtD
Pomalidomide—Muscle spasms—Doxorubicin—thyroid cancer	0.000218	0.000891	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000217	0.00547	CbGpPWpGaD
Pomalidomide—Cough—Epirubicin—thyroid cancer	0.000214	0.000874	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—thyroid cancer	0.00021	0.000857	CcSEcCtD
Pomalidomide—Arthralgia—Epirubicin—thyroid cancer	0.000209	0.000853	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—thyroid cancer	0.000208	0.00085	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000207	0.000847	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000205	0.00517	CbGpPWpGaD
Pomalidomide—Vertigo—Doxorubicin—thyroid cancer	0.000204	0.000833	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—thyroid cancer	0.000203	0.00083	CcSEcCtD
Pomalidomide—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000203	0.00511	CbGpPWpGaD
Pomalidomide—Confusional state—Epirubicin—thyroid cancer	0.000202	0.000824	CcSEcCtD
Pomalidomide—Infection—Epirubicin—thyroid cancer	0.000199	0.000812	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000198	0.00499	CbGpPWpGaD
Pomalidomide—Cough—Doxorubicin—thyroid cancer	0.000198	0.000809	CcSEcCtD
Pomalidomide—Nervous system disorder—Epirubicin—thyroid cancer	0.000196	0.000802	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—thyroid cancer	0.000196	0.0008	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—thyroid cancer	0.000194	0.000794	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—thyroid cancer	0.000194	0.00487	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Epirubicin—thyroid cancer	0.000194	0.00079	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—thyroid cancer	0.000193	0.000789	CcSEcCtD
Pomalidomide—Anxiety—Doxorubicin—thyroid cancer	0.000193	0.000786	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000192	0.000784	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000187	0.0047	CbGpPWpGaD
Pomalidomide—Confusional state—Doxorubicin—thyroid cancer	0.000187	0.000763	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—thyroid cancer	0.000184	0.000751	CcSEcCtD
Pomalidomide—CRBN—lymph node—thyroid cancer	0.000183	0.0737	CbGeAlD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000182	0.000745	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—HIF1A—thyroid cancer	0.000182	0.00457	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Doxorubicin—thyroid cancer	0.000182	0.000742	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000181	0.000741	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—thyroid cancer	0.000181	0.000739	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00018	0.00453	CbGpPWpGaD
Pomalidomide—Skin disorder—Doxorubicin—thyroid cancer	0.00018	0.000735	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000179	0.000731	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000179	0.0045	CbGpPWpGaD
Pomalidomide—Dyspnoea—Epirubicin—thyroid cancer	0.000179	0.000729	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000176	0.00443	CbGpPWpGaD
Pomalidomide—Decreased appetite—Epirubicin—thyroid cancer	0.000174	0.000711	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000173	0.000706	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—thyroid cancer	0.000173	0.000705	CcSEcCtD
Pomalidomide—Pain—Epirubicin—thyroid cancer	0.000171	0.000699	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—thyroid cancer	0.000171	0.000699	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000169	0.000689	CcSEcCtD
Pomalidomide—Insomnia—Doxorubicin—thyroid cancer	0.000168	0.000684	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000166	0.00418	CbGpPWpGaD
Pomalidomide—Dyspnoea—Doxorubicin—thyroid cancer	0.000165	0.000674	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—thyroid cancer	0.000165	0.000674	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—NRAS—thyroid cancer	0.000163	0.00409	CbGpPWpGaD
Pomalidomide—Decreased appetite—Doxorubicin—thyroid cancer	0.000161	0.000657	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00016	0.000653	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—thyroid cancer	0.00016	0.000652	CcSEcCtD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000159	0.004	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000159	0.004	CbGpPWpGaD
Pomalidomide—Constipation—Doxorubicin—thyroid cancer	0.000158	0.000647	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—thyroid cancer	0.000158	0.000647	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—thyroid cancer	0.000158	0.000646	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000158	0.00398	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000157	0.00395	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—PPARG—thyroid cancer	0.000155	0.00389	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Doxorubicin—thyroid cancer	0.000153	0.000623	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—AKT1—thyroid cancer	0.000151	0.0038	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Epirubicin—thyroid cancer	0.000148	0.000602	CcSEcCtD
Pomalidomide—Body temperature increased—Doxorubicin—thyroid cancer	0.000146	0.000598	CcSEcCtD
Pomalidomide—Asthenia—Epirubicin—thyroid cancer	0.000144	0.000586	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000143	0.00361	CbGpPWpGaD
Pomalidomide—Pruritus—Epirubicin—thyroid cancer	0.000142	0.000578	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—KRAS—thyroid cancer	0.00014	0.00352	CbGpPWpGaD
Pomalidomide—TNF—TGF-beta Receptor Signaling—HRAS—thyroid cancer	0.00014	0.00352	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000137	0.00345	CbGpPWpGaD
Pomalidomide—Diarrhoea—Epirubicin—thyroid cancer	0.000137	0.000559	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000136	0.000557	CcSEcCtD
Pomalidomide—TNF—Ceramide signaling pathway—AKT1—thyroid cancer	0.000136	0.00341	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000134	0.00338	CbGpPWpGaD
Pomalidomide—Asthenia—Doxorubicin—thyroid cancer	0.000133	0.000543	CcSEcCtD
Pomalidomide—Dizziness—Epirubicin—thyroid cancer	0.000132	0.000541	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—thyroid cancer	0.000131	0.00331	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—thyroid cancer	0.000131	0.0033	CbGpPWpGaD
Pomalidomide—Pruritus—Doxorubicin—thyroid cancer	0.000131	0.000535	CcSEcCtD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000129	0.00324	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000129	0.00324	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000128	0.00322	CbGpPWpGaD
Pomalidomide—Vomiting—Epirubicin—thyroid cancer	0.000127	0.00052	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—thyroid cancer	0.000127	0.000517	CcSEcCtD
Pomalidomide—Rash—Epirubicin—thyroid cancer	0.000126	0.000515	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—thyroid cancer	0.000126	0.000515	CcSEcCtD
Pomalidomide—Headache—Epirubicin—thyroid cancer	0.000125	0.000512	CcSEcCtD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—thyroid cancer	0.000125	0.00315	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—NRAS—thyroid cancer	0.000125	0.00314	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—thyroid cancer	0.000124	0.00313	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000123	0.00309	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BRAF—thyroid cancer	0.000123	0.00309	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—thyroid cancer	0.000123	0.0005	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000122	0.00307	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—AKT1—thyroid cancer	0.000122	0.00306	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HRAS—thyroid cancer	0.000119	0.003	CbGpPWpGaD
Pomalidomide—Nausea—Epirubicin—thyroid cancer	0.000119	0.000486	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CCND1—thyroid cancer	0.000119	0.00299	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—AKT1—thyroid cancer	0.000118	0.00297	CbGpPWpGaD
Pomalidomide—Vomiting—Doxorubicin—thyroid cancer	0.000118	0.000481	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—thyroid cancer	0.000117	0.000477	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—thyroid cancer	0.000117	0.000476	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—thyroid cancer	0.000116	0.000474	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000116	0.00291	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000111	0.0028	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—thyroid cancer	0.00011	0.000449	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—TP53—thyroid cancer	0.000108	0.00271	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—KRAS—thyroid cancer	0.000107	0.0027	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—thyroid cancer	0.000103	0.00258	CbGpPWpGaD
Pomalidomide—PTGS2—trachea—thyroid cancer	0.000102	0.0408	CbGeAlD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	9.95e-05	0.0025	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	9.83e-05	0.00247	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	9.77e-05	0.00246	CbGpPWpGaD
Pomalidomide—CYP1A2—thyroid gland—thyroid cancer	9.71e-05	0.039	CbGeAlD
Pomalidomide—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	9.64e-05	0.00242	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	9.14e-05	0.0023	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—HRAS—thyroid cancer	9.13e-05	0.0023	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDK1—thyroid cancer	9.07e-05	0.00228	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TRIM24—thyroid cancer	9.03e-05	0.00227	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	8.94e-05	0.00225	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MINPP1—thyroid cancer	8.89e-05	0.00224	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thyroid cancer	8.67e-05	0.00218	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—thyroid cancer	8.67e-05	0.00218	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CHST14—thyroid cancer	8.49e-05	0.00214	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RXRA—thyroid cancer	8.42e-05	0.00212	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	8.3e-05	0.00209	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.08e-05	0.00203	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—AKT1—thyroid cancer	8.06e-05	0.00203	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TRIM33—thyroid cancer	8.05e-05	0.00202	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	7.89e-05	0.00199	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—thyroid cancer	7.82e-05	0.00197	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.8e-05	0.00196	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—NRAS—thyroid cancer	7.71e-05	0.00194	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	7.6e-05	0.00191	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NDUFA13—thyroid cancer	7.56e-05	0.0019	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—AKT1—thyroid cancer	7.42e-05	0.00187	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	7.34e-05	0.00185	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	7.28e-05	0.00183	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	7.14e-05	0.0018	CbGpPWpGaD
Pomalidomide—PTGS2—head—thyroid cancer	7.13e-05	0.0287	CbGeAlD
Pomalidomide—PTGS2—Metabolism—CHST14—thyroid cancer	7.11e-05	0.00179	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—RXRA—thyroid cancer	6.85e-05	0.00172	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—KRAS—thyroid cancer	6.63e-05	0.00167	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	6.54e-05	0.00165	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MINPP1—thyroid cancer	6.3e-05	0.00159	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—thyroid cancer	6.29e-05	0.00158	CbGpPWpGaD
Pomalidomide—ABCB1—trachea—thyroid cancer	6.29e-05	0.0253	CbGeAlD
Pomalidomide—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	6.07e-05	0.00153	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.99e-05	0.00151	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—thyroid cancer	5.9e-05	0.00148	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	5.79e-05	0.00146	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—HPGD—thyroid cancer	5.73e-05	0.00144	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	5.56e-05	0.0014	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TCF7L1—thyroid cancer	5.37e-05	0.00135	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NDUFA13—thyroid cancer	5.36e-05	0.00135	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.32e-05	0.00134	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PPARG—thyroid cancer	5.31e-05	0.00134	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—AKT1—thyroid cancer	5.31e-05	0.00134	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—RXRA—thyroid cancer	5.29e-05	0.00133	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CHST14—thyroid cancer	5.04e-05	0.00127	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MINPP1—thyroid cancer	5.03e-05	0.00127	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	5e-05	0.00126	CbGpPWpGaD
Pomalidomide—PTGS2—lymph node—thyroid cancer	4.99e-05	0.0201	CbGeAlD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.98e-05	0.00125	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.98e-05	0.00125	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—AKT1—thyroid cancer	4.98e-05	0.00125	CbGpPWpGaD
Pomalidomide—ABCB1—thyroid gland—thyroid cancer	4.97e-05	0.02	CbGeAlD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.9e-05	0.00123	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	4.84e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.82e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.65e-05	0.00117	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	4.61e-05	0.00116	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.49e-05	0.00113	CbGpPWpGaD
Pomalidomide—ABCB1—head—thyroid cancer	4.41e-05	0.0177	CbGeAlD
Pomalidomide—CYP1A2—Metabolism—NDUFA13—thyroid cancer	4.28e-05	0.00108	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—HPGD—thyroid cancer	4.06e-05	0.00102	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CHST14—thyroid cancer	4.02e-05	0.00101	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TPR—thyroid cancer	3.93e-05	0.000989	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.92e-05	0.000986	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.88e-05	0.000977	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PRKAR1A—thyroid cancer	3.87e-05	0.000973	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.73e-05	0.000938	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.7e-05	0.000931	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MEN1—thyroid cancer	3.7e-05	0.00093	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.54e-05	0.000891	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	3.42e-05	0.00086	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NDUFA13—thyroid cancer	3.3e-05	0.000831	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TPR—thyroid cancer	3.29e-05	0.000828	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.29e-05	0.000828	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—NRAS—thyroid cancer	3.25e-05	0.000818	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—HPGD—thyroid cancer	3.24e-05	0.000816	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PRKAR1A—thyroid cancer	3.24e-05	0.000815	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.13e-05	0.000788	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CHST14—thyroid cancer	3.1e-05	0.000781	CbGpPWpGaD
Pomalidomide—ABCB1—lymph node—thyroid cancer	3.09e-05	0.0124	CbGeAlD
Pomalidomide—PTGS2—Disease—CALCA—thyroid cancer	2.94e-05	0.00074	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.93e-05	0.000738	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—KRAS—thyroid cancer	2.8e-05	0.000704	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.78e-05	0.000699	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDK1—thyroid cancer	2.66e-05	0.00067	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.63e-05	0.000662	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.62e-05	0.00066	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—HPGD—thyroid cancer	2.5e-05	0.00063	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.46e-05	0.00062	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—HRAS—thyroid cancer	2.38e-05	0.000599	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TPR—thyroid cancer	2.33e-05	0.000587	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.33e-05	0.000587	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.3e-05	0.000577	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRG1—thyroid cancer	2.14e-05	0.000538	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—AKT1—thyroid cancer	2.1e-05	0.000528	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RXRA—thyroid cancer	2.07e-05	0.000521	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.01e-05	0.000507	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.97e-05	0.000496	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TERT—thyroid cancer	1.92e-05	0.000483	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TPR—thyroid cancer	1.86e-05	0.000469	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HIF1A—thyroid cancer	1.84e-05	0.000462	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.83e-05	0.000461	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.75e-05	0.000439	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.66e-05	0.000418	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—thyroid cancer	1.52e-05	0.000382	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RXRA—thyroid cancer	1.47e-05	0.000369	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TPR—thyroid cancer	1.44e-05	0.000362	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.41e-05	0.000356	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.39e-05	0.000351	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PPARG—thyroid cancer	1.31e-05	0.000329	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.31e-05	0.000329	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RXRA—thyroid cancer	1.17e-05	0.000295	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.14e-05	0.000287	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.08e-05	0.000271	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PTEN—thyroid cancer	1.07e-05	0.000269	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NRAS—thyroid cancer	9.55e-06	0.00024	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PPARG—thyroid cancer	9.27e-06	0.000233	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RXRA—thyroid cancer	9.04e-06	0.000227	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PTEN—thyroid cancer	8.97e-06	0.000226	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KRAS—thyroid cancer	8.22e-06	0.000207	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PPARG—thyroid cancer	7.4e-06	0.000186	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—thyroid cancer	7.29e-06	0.000183	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HRAS—thyroid cancer	6.99e-06	0.000176	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTEN—thyroid cancer	6.36e-06	0.00016	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—AKT1—thyroid cancer	6.17e-06	0.000155	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.82e-06	0.000146	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PPARG—thyroid cancer	5.71e-06	0.000144	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AKT1—thyroid cancer	5.17e-06	0.00013	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTEN—thyroid cancer	5.07e-06	0.000128	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—thyroid cancer	4.49e-06	0.000113	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTEN—thyroid cancer	3.92e-06	9.85e-05	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AKT1—thyroid cancer	3.66e-06	9.22e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AKT1—thyroid cancer	2.92e-06	7.36e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AKT1—thyroid cancer	2.26e-06	5.68e-05	CbGpPWpGaD
